Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types

Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types

Monday, August 10, 2020
Webinar -- 6:00 PM ET


Welcome and Introduction

The Immunotherapy Revolution: Current Indications and Biomarker Development

A Focus on GI Cancers and MMR/MSI-H

A Focus on GU Cancers: Current Clinical Experience With PD-1/PD-L1 Immune Checkpoint Inhibitors

A Focus on Lung Cancer: The Role of PD-L1 in IO Therapy Selection

On the Horizon: Biomarker Development, Tumor Mutation Burden, Emerging Biomarkers, Blood-Based Biopsies, Testing Platforms

Audience Question and Answer Session and Final Thoughts


Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Jamie Chaft, MD

Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Scot Niglio, MD

Medical Oncologist
Bethesda, Maryland

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers of immune checkpoint inhibitor therapies so they can confidently and competently integrate these treatments into clinical practice.

Target Audience
This program is intended for physicians and other relevant healthcare and laboratory professionals who treat/manage patients with cancer who are candidates for immunotherapies (including the utility of current and emerging biomarkers to guide cancer treatment with immunotherapies across tumor types).

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe recent data on current and emerging biomarkers that predict response to immunotherapy and guide treatment selection across tumor types
  • Discuss the challenges and limitations associated with current and emerging biomarkers including tissue sampling, testing platforms, scoring, and interpretation of results
  • Evaluate evidence on emerging tumor and immune predictive biomarkers and their associated testing platforms
  • Explain the potential benefits of incorporating blood-based or serum-based biomarkers and testing into clinical practice
  • Incorporate expert and guideline recommendations for biomarker testing into clinical practice based on tumor characteristics, using appropriate biopsy sampling and diagnostic testing platforms


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.